Video Interview: Keryx Reboots Disappointing Product Launch
This article was originally published in Scrip
Keryx Biopharmaceuticals CEO Greg Madison reveals to Mike Ward, global director of content for Informa's pharma insights portfolio, how the company turned around what was initially a disappointing launch of the company's first product. Auryxia (ferric citrate) was first launched in 2015 for the control of serum phosphorus levels in dialysis patients with chronic kidney disease. However, as Madison notes, the launch got off to a rough start with slow sales and a chorus of naysayers. Madison explains how the company revisited its launch strategy, resulting in an increase in sales. The company is now looking at a potential label extension in the US, based on data from a Phase III pivotal study evaluating Auryxia in pre-dialysis patients with iron deficiency anemia—topline results expected in 2Q 2016—and expects to identify a partner for the European market after being granted a strong label for EU marketing authorization in 2015.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.